Ocular Hypertension News

Ocular Therapeutix Commences a Sustained Release Travoprost Punctum Plug ... - MarketWatch (press release)



Ocular Therapeutix Commences a Sustained Release Travoprost Punctum Plug ... 
MarketWatch (press release)
Patients with documented ocular hypertension or open-angle glaucoma are eligible for the study. Primary endpoints include intraocular pressure reduction from baseline and retention of the plug through 30 days. This study will be the first in a series, ...

and more » 


Ocular Therapeutix Commences a Sustained Release Travoprost Punctum Plug ... - PR Newswire (press release)



Ocular Therapeutix Commences a Sustained Release Travoprost Punctum Plug ... 
PR Newswire (press release)
Patients with documented ocular hypertension or open-angle glaucoma are eligible for the study. Primary endpoints include intraocular pressure reduction from baseline and retention of the plug through 30 days. This study will be the first in a series, ...

and more » 


Merck Worth $41: Shows Solid Growth And Cost Controls - Forbes



Merck Worth $41: Shows Solid Growth And Cost Controls 
Forbes
Zioptan, a drug prescribed for ophthalmic symptoms received the FDA's nod for use in cases of ocular hypertension. Ocular hypertension is a condition characterized by an increase in pressure inside the eye. Merck recently also ventured into developing ...

and more » 


pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012 - MarketWatch (press release)



pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012 
MarketWatch (press release)
"In collaboration with Pfizer, we are also continuing to progress development of our bioerodible insert to treat glaucoma and ocular hypertension," said Dr. Ashton. The Company's proposed product candidate is an injectable, bioerodible sustained ...

and more » 


pSivida Corp. Announces Expiration of 2.7 Million Warrants - MarketWatch (press release)



pSivida Corp. Announces Expiration of 2.7 Million Warrants 
MarketWatch (press release)
... New Drug application is open for an injectable insert of the same design as ILUVIEN for DME to treat posterior uveitis, and an investigator-sponsored trial is ongoing for an injectable, bioerodible insert to treat glaucoma and ocular hypertension.

and more » 


Acucela Announces New Data from Its Phase 2a Trial of ACU-4429 in Patients ... - MarketWatch (press release)



Acucela Announces New Data from Its Phase 2a Trial of ACU-4429 in Patients ... 
MarketWatch (press release)
OPA-6566, an adenosine A2a receptor agonist, is being investigated as an ophthalmic solution for lowering intraocular pressure in open-angle glaucoma or ocular hypertension patients. Acucela Inc. Francesca T. Nolan, 206-805-8300 Director Corporate ...

and more » 


Allergan Reports First Quarter 2012 Operating Results - MarketWatch (press release)



Allergan Reports First Quarter 2012 Operating Results 
MarketWatch (press release)
On January 18, 2012, Senju Pharmaceutical Co., Ltd received approval from the Japanese Ministry of Health, Labour and Welfare for AIPHAGAN(R) P Ophthalmic Solution 0.1% for the reduction of intraocular pressure in patients with ocular hypertension ...

and more » 


Recent publicly-funded CATT trial highlights serious safety concerns around ... - MarketWatch (press release)



Recent publicly-funded CATT trial highlights serious safety concerns around ... 
MarketWatch (press release)
Basel, Switzerland, May 01, 2012 (Thomson Reuters ONE via COMTEX) -- Novartis International AG / Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis .
Recent publicly-funded CATT trial highlights serious safety concerns The FINANCIAL

all 44 news articles » 


pSivida Corp. Announces Expiration of 2.7 Million Warrants - SunHerald.com



pSivida Corp. Announces Expiration of 2.7 Million Warrants 
SunHerald.com
... New Drug application is open for an injectable insert of the same design as ILUVIEN for DME to treat posterior uveitis, and an investigator-sponsored trial is ongoing for an injectable, bioerodible insert to treat glaucoma and ocular hypertension.

and more » 


Merck Announces First-Quarter 2012 Financial Results - MarketWatch (press release)



Merck Announces First-Quarter 2012 Financial Results 
MarketWatch (press release)
Received FDA approval for ZIOPTAN (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

and more »